V. Méresse

发表

Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial.

A. Grañena, J. Reiffers, R. Schots, 1999, Blood.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

P. Paschka, G. Martinelli, W. Fiedler, 2016, Oncotarget.

First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors

J. Desai, J. Tabernero, M. Brown, 2016, Targeted Oncology.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma

M. Venturi, D. Skene, P. Workman, 2017, Molecular Cancer Therapeutics.

Peripheral Blood Stem Cell and Bone Marrow Transplantation for Solid Tumors and Lymphomas: Hematologic Recovery and Costs: A Randomized, Controlled Trial

D. Blaise, I. Philip, J. Michon, 1997, Annals of Internal Medicine.

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.

P. Varlet, D. Frappaz, X. Paoletti, 2011, Neuro-oncology.

Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.

G. Vassal, L. Brugières, D. Valteau‐Couanet, 1992, Bone marrow transplantation.

Screening for germ line p53 mutations in children with malignant tumors and a family history of cancer.

C. Bonaïti‐pellié, N. Poisson, A. Chompret, 1993, Cancer research.

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

Fabian Birzele, E. Voss, H. Verheul, 2015, Clinical Cancer Research.

Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients.

J. Blay, W. Brugger, P. Viens, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models

S. Stone-Elander, P. Pisa, J. Tessier, 2013, EJNMMI Research.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.

P. Varlet, D. Frappaz, X. Paoletti, 2011, Neuro-oncology.

Evaluation and validation of diagnostic tests for guiding therapeutic decisions.

Paul Landais, Valérie Méresse, Jean-Claude Ghislain, 2009, Therapie.

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

Li Lu, Michael Pawlak, Jean Tessier, 2014, EJNMMI Research.

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

T. Nayak, H. Verheul, D. Mahalingam, 2016, Oncotarget.